BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens
Closed Pre-Solicitation Posted
- Solicitation number
- BARDA-CBRN-11042024
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Washington, District of Columbia, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, through the Center for the Biomedical Advanced Research and Development Authority (BARDA), is conducting market research on antibiotics in development for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI) caused by drug-resistant bacteria, as well as for post-exposure prophylaxis and/or treatment of biothreat pathogens. BARDA is seeking information on antibiotic programs that expect to have their end-of-Phase 2 FDA meeting by May 1, 2025, with the intended indication of treating HABP/VABP, BSI, or both, potentially including a biothreat indication. Respondents are asked to provide details on the antibiotic candidate, nonclinical and clinical development status, manufacturing capabilities, procurement and commercialization plans. Responses are due by Noon EST on November 29, 2024.
This is an open market research exercise, with no set-aside designations, and there are no incumbent contractors identified. The anticipated award value or budget range is not specified. The NAICS code is 541714 - Research and Development in Biotechnology, and the PSC code is AB11 - Community And Regional Development R&D Services.
Notice text
The subject of this Sources Sought Notice is to gain information regarding antibiotics in development for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI) caused by drug-resistant bacterial infections. Proposed antibiotics may also be developed for post-exposure prophylaxis and/or treatment of biothreat pathogens (Yersinia pestis, Francella tularensis, Burkholderia pseudomallei, and Bacillus anthracis).
Files
| File | Type | Posted |
|---|---|---|
| PBS AMR 2025 SSN - Final.docx | DOCX document | |
| PBS AMR 2025 SSN - Final.docx | DOCX document |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity